ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 144 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2021. The put-call ratio across all filers is 2.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $263,114 | -7.2% | 268,484 | +31.6% | 0.00% | – |
| Q2 2023 | $283,660 | +5.6% | 204,072 | +20.8% | 0.00% | – |
| Q1 2023 | $268,509 | -29.9% | 168,874 | +174.8% | 0.00% | – |
| Q4 2022 | $382,802 | +147.0% | 61,445 | +165.8% | 0.00% | – |
| Q3 2022 | $155,000 | -3.7% | 23,115 | -9.0% | 0.00% | – |
| Q2 2022 | $161,000 | -61.6% | 25,388 | -71.9% | 0.00% | – |
| Q1 2022 | $419,000 | -44.4% | 90,300 | -40.0% | 0.00% | – |
| Q4 2021 | $753,000 | -46.7% | 150,607 | +28.3% | 0.00% | – |
| Q3 2021 | $1,414,000 | +150.3% | 117,372 | +339.6% | 0.00% | – |
| Q2 2021 | $565,000 | -59.9% | 26,700 | -46.8% | 0.00% | – |
| Q1 2021 | $1,408,000 | -61.0% | 50,185 | -63.8% | 0.00% | -100.0% |
| Q4 2020 | $3,608,000 | -12.4% | 138,768 | +25.3% | 0.00% | -50.0% |
| Q3 2020 | $4,117,000 | -52.8% | 110,762 | -34.8% | 0.00% | -66.7% |
| Q2 2020 | $8,721,000 | +2091.2% | 169,961 | +1244.2% | 0.01% | – |
| Q1 2020 | $398,000 | -87.7% | 12,644 | -76.7% | 0.00% | -100.0% |
| Q4 2019 | $3,233,000 | +826.4% | 54,226 | +468.9% | 0.01% | +400.0% |
| Q3 2019 | $349,000 | -47.2% | 9,531 | -33.6% | 0.00% | -50.0% |
| Q4 2018 | $661,000 | -62.0% | 14,359 | -63.4% | 0.00% | -50.0% |
| Q3 2018 | $1,741,000 | +706.0% | 39,253 | +613.7% | 0.00% | +300.0% |
| Q2 2018 | $216,000 | -74.7% | 5,500 | -53.4% | 0.00% | -50.0% |
| Q1 2018 | $853,000 | -69.2% | 11,800 | -71.9% | 0.00% | -75.0% |
| Q4 2017 | $2,768,000 | +29.5% | 42,049 | -1.4% | 0.01% | +14.3% |
| Q3 2017 | $2,138,000 | +148.0% | 42,647 | +128.9% | 0.01% | +133.3% |
| Q2 2017 | $862,000 | -80.7% | 18,632 | -85.3% | 0.00% | -85.7% |
| Q1 2017 | $4,471,000 | +1468.8% | 126,647 | +651.7% | 0.02% | +950.0% |
| Q1 2016 | $285,000 | -59.2% | 16,847 | -43.1% | 0.00% | -50.0% |
| Q3 2015 | $699,000 | -72.6% | 29,633 | +7.6% | 0.00% | -80.0% |
| Q1 2015 | $2,551,000 | +663.8% | 27,550 | +233.8% | 0.02% | +566.7% |
| Q4 2014 | $334,000 | -66.6% | 8,254 | -79.8% | 0.00% | -70.0% |
| Q3 2014 | $1,001,000 | – | 40,907 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |